New insights into the biochemistry of pain are starting to pay off in safer, and perhaps even more effective, treatment options for chronic sufferers.
The drugs appear to be no more effective at fighting pain than traditional anti-inflammatory medications such as ibuprofen and aspirin, but offer the advantage of fewer side effects.
A different drug of the same type, Merck Co.'s Vioxx, is awaiting approval by the Food and Drug Administration and could be on the market by summer.
COX-2 drugs are designed primarily for those with rheumatoid arthritis, which afflicts about 2.1 million people in the United States, and for painful flareups of osteoarthritis, the ``wear-and-tear'' form of the ailment, which affects an estimated 20.7 million people.
The drug, made by Immunex Corp. of Seattle, was approved by the FDA last year1998cq for use in adults.
NEW YORK (AP) _ The pharmaceutical industry is announcing big gains in the fight against arthritis this week, with several companies reporting they can now reduce pain and slow progression of the often debilitating illness.
The federal government has approved two new drugs to treat rheumatoid arthritis since September, drugs that aim to help those with moderate-to-severe forms of the disease.
But industry observers say the biggest advances will occur next year with the expected approval of arthritis drugs made by Searle Inc. and Merck and Co.
These drugs will treat the pain and inflammation associated with arthritis without the stomach problems associated with today's over-the-counter and prescription drugs,
